カテゴリ： GlobalData, フランス, 企業調査

Les Laboratoires Servier SAS：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Les Laboratoires Servier SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3319
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：90
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Les Laboratoires Servier SAS (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company’s portfolio of marketed products treat central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women’s and male health issues, gastrointestinal diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) worldwide. The company also provides generic drugs and contract development and manufacturing services across its global network. Servier sells its products in Europe, North America, South America, Middle East, Africa and Asia. Servier headquartered in Suresnes, France.

Les Laboratoires Servier SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 12
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Les Laboratoires Servier to Acquire Oncology Business from Shire for USD2.4 Billion 17
Egis Pharma Acquires Sorbifer Rights from AstraZeneca 19
Venture Financing 20
Ilkos Therapeutics Raises USD14 Million in Seed Financing 20
Partnerships 21
Les Laboratoires Servier and ScandiCure Enter into Agreement 21
ImmunoQure Enters into Agreement with Servier 22
Les Laboratoires Enters into Agreement with Treventis 23
Les Laboratoires Servier Enters into Agreement with Harvard University 24
Philochem Enters into Research Agreement with Les Laboratoires Servier 25
Servier and Transgene Enters into Research Agreement 26
Vernalis and Servier Enter into Discovery Agreement 27
Les Laboratoires Servier and Masthercell Enter into Agreement 28
Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29
Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30
Spectrum Pharma Enters into Agreement with Servier Canada 31
Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32
Vect-Horus Enters into Agreement with Servier 33
GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 35
Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 36
Servier Expands Agreement with Novartis 37
Cellectis Enters Into Co-Development Agreement With Servier 38
Institut Curie Extends Research Agreement with Servier 40
Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 41
Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 42
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 43
Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 44
NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 45
Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 46
Les Labs Servier Enters Into Research Agreement With Monash Institute 48
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 49
Licensing Agreements 50
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 50
Servier Enters into Licensing Agreement with Numerate 51
Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 52
Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 53
Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 54
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 56
Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 57
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 58
Pfizer Enters into Licensing Agreement with Servier for UCART19 59
Servier Exercises Option for Licensing Agreement with Cellectis 60
Horizon Discovery Enters into Licensing Agreement with Servier Lab 61
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62
Taiho Pharma Enters into Licensing Agreement with Servier 63
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 64
Celladon Enters Into Option For Licensing Agreement With Servier 66
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 67
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 69
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 70
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 71
Asset Transactions 73
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 73
Acquisition 74
Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 74
Les Laboratoires Servier SAS – Key Competitors 76
Les Laboratoires Servier SAS – Key Employees 77
Les Laboratoires Servier SAS – Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Recent Developments 81
Financial Announcements 81
Feb 22, 2018: Servier Announces 2017 annual results 81
Feb 07, 2017: Servier announces an increase in turnover for 2015-2016 83
Corporate Communications 84
Mar 06, 2018: Servier appoints a Chief Patient Officer 84
Product News 85
03/09/2017: Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia 85
Clinical Trials 86
Mar 08, 2018: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting 86
Dec 12, 2017: Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials 87
Nov 01, 2017: Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting 88
Other Significant Developments 89
Jul 04, 2018: Servier Netherlands mobilizes for Stem Cell Donation 89
Appendix 90
Methodology 90
About GlobalData 90
Contact Us 90
Disclaimer 90

List of Tables
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Les Laboratoires Servier SAS, Deals By Therapy Area, 2012 to YTD 2018 10
Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 12
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Les Laboratoires Servier to Acquire Oncology Business from Shire for USD2.4 Billion 17
Egis Pharma Acquires Sorbifer Rights from AstraZeneca 19
Ilkos Therapeutics Raises USD14 Million in Seed Financing 20
Les Laboratoires Servier and ScandiCure Enter into Agreement 21
ImmunoQure Enters into Agreement with Servier 22
Les Laboratoires Enters into Agreement with Treventis 23
Les Laboratoires Servier Enters into Agreement with Harvard University 24
Philochem Enters into Research Agreement with Les Laboratoires Servier 25
Servier and Transgene Enters into Research Agreement 26
Vernalis and Servier Enter into Discovery Agreement 27
Les Laboratoires Servier and Masthercell Enter into Agreement 28
Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29
Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30
Spectrum Pharma Enters into Agreement with Servier Canada 31
Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32
Vect-Horus Enters into Agreement with Servier 33
GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 35
Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 36
Servier Expands Agreement with Novartis 37
Cellectis Enters Into Co-Development Agreement With Servier 38
Institut Curie Extends Research Agreement with Servier 40
Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 41
Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 42
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 43
Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 44
NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 45
Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 46
Les Labs Servier Enters Into Research Agreement With Monash Institute 48
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 49
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 50
Servier Enters into Licensing Agreement with Numerate 51
Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 52
Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 53
Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 54
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 56
Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 57
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 58
Pfizer Enters into Licensing Agreement with Servier for UCART19 59
Servier Exercises Option for Licensing Agreement with Cellectis 60
Horizon Discovery Enters into Licensing Agreement with Servier Lab 61
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62
Taiho Pharma Enters into Licensing Agreement with Servier 63
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 64
Celladon Enters Into Option For Licensing Agreement With Servier 66
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 67
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 69
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 70
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 71
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 73
Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 74
Les Laboratoires Servier SAS, Key Competitors 76
Les Laboratoires Servier SAS, Key Employees 77
Les Laboratoires Servier SAS, Subsidiaries 78

List of Figures
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Les Laboratoires Servier SAS：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hertz Global Holdings Inc：企業の戦略・SWOT・財務情報
    Hertz Global Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Hertz Global Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Innsuites Hospitality Trust：企業の戦略・SWOT・財務分析
    Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report Summary Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Coca-Cola Amatil Limited：戦略・SWOT・企業財務分析
    Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Shinko Electric Industries Co., Ltd.：企業の戦略・SWOT・財務情報
    Shinko Electric Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shinko Electric Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Caterpillar Inc (CAT)-エネルギー分野：企業M&A・提携分析
    Summary Caterpillar Inc. (Caterpillar) is a manufacturer of construction, transportation and energy equipment. It designs, manufactures, markets and sells construction and mining equipment, industrial gas turbines, forestry machinery, diesel and natural gas engines, and diesel-electric locomotives. …
  • Discovery Holdings Limited (DSY)：企業の財務・戦略的SWOT分析
    Discovery Holdings Limited (DSY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • EBOS Group Ltd (EBO)：製薬・医療：M&Aディール及び事業提携情報
    Summary EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and med …
  • Abbott Diabetes Care Inc：医療機器：M&Aディール及び事業提携情報
    Summary Abbott Diabetes Care Inc (ADC), formerly TheraSense Inc, a subsidiary of Abbott Laboratories, is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitor …
  • Araca Energy ASA：石油・ガス：M&Aディール及び事業提携情報
    Summary Araca Energy ASA (Araca Energy), formerly Aladdin Oil & Gas Company ASA is an oil and gas company that explores, acquires, extracts, develops, and produces oil and gas assets in Russia and other countries. The company conducts its oil and gas exploration, production and operations through it …
  • HoMedics LLC：企業の戦略的SWOT分析
    HoMedics LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • NorthWestern Corporation (NWE)-エネルギー分野：企業M&A・提携分析
    Summary NorthWestern Corporation, doing business as NorthWestern Energy, is an integrated electric utility which generates, transmits, and distributes electricity and distributes natural gas in South Dakota, Nebraska and Montana. It produces energy from wind, hydro, natural gas, and coal-fired sourc …
  • Zion Oil & Gas Inc (ZN)：石油・ガス：M&Aディール及び事業提携情報
    Summary Zion Oil & Gas Inc (Zion Oil) is an oil and gas company that explores and produces oil and gas properties in Israel. The company offers services such as geophysical, geological, and other science-based studies and surveys to support oil and gas exploration and development services. It holds …
  • American Family Insurance Group：企業の戦略・SWOT・財務情報
    American Family Insurance Group - Strategy, SWOT and Corporate Finance Report Summary American Family Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Fischer Connectors UK：企業の戦略・SWOT・財務情報
    Fischer Connectors UK - Strategy, SWOT and Corporate Finance Report Summary Fischer Connectors UK - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CMC Materials Inc (CCMP)：企業の財務・戦略的SWOT分析
    CMC Materials Inc (CCMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • TransMontaigne Product Services LLC-石油・ガス分野：企業M&A・提携分析
    Summary TransMontaigne Product Services LLC (TransMontaigne), a subsidiary of NGL Energy Partners LP, is an energy company, which carries out distribution and marketing of a wide range of petroleum products. The company markets several products including unbranded gasoline, diesel fuel, heating oil, …
  • OJSC Rosneft Oil Company：企業の戦略・SWOT・財務分析
    OJSC Rosneft Oil Company - Strategy, SWOT and Corporate Finance Report Summary OJSC Rosneft Oil Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cherkizovo Group OJSC (GCHE)：企業の財務・戦略的SWOT分析
    Cherkizovo Group OJSC (GCHE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Union Jack Oil plc (UJO)：石油・ガス：M&Aディール及び事業提携情報
    Summary Union Jack Oil plc (Union Jack Oil), formerly Union Jack Oil Ltd is an onshore oil and gas company that offers exploration and development of hydrocarbon projects. The company develops its portfolio of oil and gas assets by acquiring interests in drill ready prospects. It holds license inter …
  • Wausau Paper Corporation：企業の戦略・SWOT・財務情報
    Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆